12/25/2025
Retatrutide confers up to 28.7% weight loss, reduction in knee osteoarthritis pain https://www.healio.com/news/endocrinology/20251211/retatrutide-confers-up-to-287-weight-loss-reduction-in-knee-osteoarthritis-pain
Game changer for treating osteoarthritis!
A novel triple receptor agonist conferred weight loss of up to 28.7% at 68 weeks and reductions in pain for adults with overweight or obesity and knee osteoarthritis, according to topline results from the TRIUMPH-4 trial. Retatrutide (Eli Lilly) is a once-weekly injectable GIP/GLP-1/glucagon triple....